Zobrazeno 1 - 6
of 6
pro vyhledávání: ''
Autor:
Jan-Stefan van der Walt, Joji Mori, Takahiro Nakayama, Kenichi Inoue, Yoshinori Ito, George W. Sledge, Yasuo Miyoshi, Tsutomu Kawaguchi, Masato Takahashi, Yoshinori Tanizawa, Masakazu Toi, Antonio Llombart-Cussac, Norikazu Masuda, Hiroji Iwata, Hirofumi Mukai, Sachi Sakaguchi
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-neg
Autor:
Masako Sato, Hidetoshi Kawaguchi, Satoshi Morita, Makiko Mizutani, Yoshie Hasegawa, Ken-ichi Watanabe, Yasuaki Sagara, Fumikata Hara, Takashi Morimoto, Takahiro Nakayama, Norikazu Masuda, Mitsuya Itoh, Shoichiro Ohtani, Nobuki Matsunami, Kenji Higaki, Masato Takahashi, Tetsuhiro Yoshinami
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background This study aimed to investigate whether schedule modification is safe and effective in patients intolerant to the standard eribulin dose and schedule. Methods Patients with metastatic breast cancer (MBC) treated with both anthracycline and
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background The human Y-box-binding protein 1 (YB-1) is a member of the DNA/RNA-binding family of proteins that regulates transcription and translation of genes. Previous studies suggest that YB-1 may have an oncogenic role in various cancers. In this
Autor:
Tarek Sahmoud, Yutaka Tokuda, Yoshiaki Rai, Hirotaka Iwase, Shozo Ohsumi, Hirofumi Mukai, Ashok Panneerselvam, Woo Chul Noh, Yoshinori Ito, Puttisak Puttawibul, Hideo Inaji, Tetiana Taran, Vichien Srimuninnimit, Hiroji Iwata, Norikazu Masuda, Takahiro Nakayama, Mona El-Hashimy, Shinzaburo Noguchi, Jun Horiguchi, Shinji Ohno, Katsumasa Kuroi, Byeong Woo Park
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background The addition of mTOR inhibitor everolimus (EVE) to exemestane (EXE) was evaluated in an international, phase 3 study (BOLERO-2) in patients with hormone-receptor-positive (HR+) breast cancer refractory to letrozole or anastrozole. The safe
Autor:
Masayuki Yoshida, Kenichi Sugihara, Takashi Hojo, Hitoshi Tsuda, Nobuko Tamura, Sadako Akashi-Tanaka, Takayuki Kinoshita
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background Ipsilateral breast tumor recurrence (IBTR) after partial breast resection and contralateral breast tumor recurrence (CBTR) have been shown to occur relatively frequently in patients with ductal carcinoma in situ (DCIS). However, there is o
Autor:
Katsumasa Kuroi, Seigo Nakamura, Nobuaki Sato, Hiroji Iwata, Masakazu Toi, Futoshi Akiyama, Masafumi Kurosumi, Norikazu Masuda, Hitoshi Tsuda, Shinji Ohno
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background Neoadjuvant chemotherapy (NAC) has been accepted as one of the standard treatments for operable breast cancer. However, the term pathologic complete response (pCR) has not been consistently defined. Methods This study was a pooled analysis